ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatment of Stroke
Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, is discussing with the FDA and the EMA its development program for the acute ischemic stroke (AIS) indication.
Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies
Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, has discussed with the European Medicines Agency (EMA) the design of its pivotal Phase II/III study to support a potential future marketing authorization application (MAA) for its first-in-class drug, glenzocimab.
Acticor Biotech and the University of Birmingham in the UK have entered a collaboration to conduct a Phase IIb clinical trial of the new drug, glenzocimab, for the treatment of patients with myocardial infarction (MI) or heart attacks.
Acticor Biotech, a clinical-stage biotechnology company, announced the enrollment of the first patient in the USA in its phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
Acticor Biotech has enrolled the first US subject in the Phase II/III ACTISAVE clinical trial of glenzocimab in acute ischemic stroke patients.
PARIS--(BUSINESS WIRE)--ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announces today the presentation of positive results from the Phase 1b/2a study, ACTIMIS, in the treatment of acute ischemic stroke, at the 8th European Stroke Organisation Conference (ESOC) on Friday May 6, 2022.
Acticor Biotech (Paris:ALACT), a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, today announced its full-year results for the period ended 31 December 2021, as approved by the Board of Directors on 29 March 2022, and gave an update on its clinical development. The full-year financial report will be included in a registration document due to be published on 27 April 2022.